- Home
- BEAM vs CABO Comparison
BEAM vs CABO Comparison
Compare BEAM & CABO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAM
- CABO
- Stock Information
- Founded
- BEAM 2017
- CABO 1980
- Country
- BEAM United States
- CABO United States
- Employees
- BEAM N/A
- CABO N/A
- Industry
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- CABO Cable & Other Pay Television Services
- Sector
- BEAM Health Care
- CABO Telecommunications
- Exchange
- BEAM Nasdaq
- CABO Nasdaq
- Market Cap
- BEAM 1.6B
- CABO 717.5M
- IPO Year
- BEAM 2020
- CABO N/A
- Fundamental
- Price
- BEAM $19.18
- CABO $129.57
- Analyst Decision
- BEAM Strong Buy
- CABO Hold
- Analyst Count
- BEAM 11
- CABO 3
- Target Price
- BEAM $48.90
- CABO $231.00
- AVG Volume (30 Days)
- BEAM 2.0M
- CABO 212.3K
- Earning Date
- BEAM 08-05-2025
- CABO 07-31-2025
- Dividend Yield
- BEAM N/A
- CABO 6.83%
- EPS Growth
- BEAM N/A
- CABO N/A
- EPS
- BEAM N/A
- CABO N/A
- Revenue
- BEAM $63,578,000.00
- CABO $1,555,831,000.00
- Revenue This Year
- BEAM N/A
- CABO N/A
- Revenue Next Year
- BEAM $8.82
- CABO N/A
- P/E Ratio
- BEAM N/A
- CABO N/A
- Revenue Growth
- BEAM N/A
- CABO N/A
- 52 Week Low
- BEAM $13.53
- CABO $121.37
- 52 Week High
- BEAM $35.25
- CABO $437.00
- Technical
- Relative Strength Index (RSI)
- BEAM 60.60
- CABO 39.76
- Support Level
- BEAM $16.59
- CABO $133.73
- Resistance Level
- BEAM $20.46
- CABO $147.49
- Average True Range (ATR)
- BEAM 1.13
- CABO 6.54
- MACD
- BEAM 0.34
- CABO 2.83
- Stochastic Oscillator
- BEAM 70.61
- CABO 31.39
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
About CABO Cable One Inc.
Cable One Inc. is a telecommunications company that generates revenue from providing broadband, voice, and video services to both residential and business customers. From a product standpoint, the majority of revenue comes from data and video services, which are subscription-based and billed monthly. The company also offers Sparklight TV, an Internet Protocol Television (IPTV) service that enables customers using the Sparklight TV app to stream video channels from the cloud. Additionally, the company earns advertising revenue by selling airtime on its video channels, and it provides voice services over Internet protocols. Cable One Inc. owns its telecommunications infrastructure.